Samantha Walker

Samantha Walker

Auto-generated profile, based on publicly available information

Samantha Walker

Research and Innovation, Asthma + Lung UK, London, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 1999 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SDStephen R. Durham
Stephen R. Durham
SWSamantha M. Walker
Samantha M. Walker
EVEva-Maria Varga
Eva-Maria Varga
MJMikila R. Jacobson
Mikila R. Jacobson
FOFiona O'BRien
Fiona O'BRien
KNKayhan T. Nouri-Aria
Kayhan T. Nouri-Aria
Pollen immunotherapy is effective in selected patients with IgE-mediated seasonal allergic rhinitis, although it is questionable whether there is long-term benefit after the discontinuation of treatment. We conducted a randomized, double-blind, placebo-controlled trial of the discontinuation of immunotherapy for grass-pollen allergy in patients in whom three to four years of this treatment had previously been shown to be effective. During the three years of this trial, primary outcome measures were scores for seasonal symptoms and the use of rescue medication. Objective measures included the immediate conjunctival response and the immediate and late skin responses to allergen challenge. Cutaneous-biopsy specimens obtained 24 hours after intradermal allergen challenge were examined for T-cell infiltration and the presence of cytokine-producing T helper cells (TH2 cells) (as evidenced by the presence of interleukin-4 messenger RNA). A matched group of patients with hay fever who had not received immunotherapy was followed as a control for the natural course of the disease. Scores for seasonal symptoms and the use of rescue antiallergic medication, which included short courses of prednisolone, remained low after the discontinuation of immunotherapy, and there was no significant difference between patients who continued immunotherapy and those who discontinued it. Symptom scores in both treatment groups (median areas under the curve in 1995, 921 for continuation of immunotherapy and 504 for discontinuation of immunotherapy; P=0.60) were markedly lower than those in the group that had not received immunotherapy (median value in 1995, 2863). Although there was a tendency for immediate sensitivity to allergen to return late after discontinuation, there was a sustained reduction in the late skin response and associated CD3+ T-cell infiltration and interleukin-4 messenger RNA expression. Immunotherapy for grass-pollen allergy for three to four years induces prolonged clinical remission accompanied by a persistent alteration in immunologic reactivity.

1 August 2007 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
SWSamantha Walker
Samantha Walker
SKSaba Khan-Wasti
Saba Khan-Wasti
MFMonica Fletcher
Monica Fletcher
PCPaul Cullinan
Paul Cullinan
JHJessica Harris
Jessica Harris
ASAziz Sheikh
Aziz Sheikh

1 February 2011 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
LJLouisa K. James
Louisa K. James
MSMohamed H. Shamji
Mohamed H. Shamji
SWSamantha M. Walker
Samantha M. Walker
DWDuncan R. Wilson
Duncan R. Wilson
PWPetra A. Wachholz
Petra A. Wachholz
SDStephen R. Durham
Stephen R. Durham

7 December 2007 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
GSG. K. Scadding
G. K. Scadding
SDS. R. Durham
S. R. Durham
RMR. Mirakian
R. Mirakian
NJN. S. Jones
N. S. Jones
SLS. C. Leech
S. C. Leech
SNS. M. Nasser
S. M. Nasser
Summary: This guidance for the management of patients with allergic and non‐allergic rhinitis has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is for use by both adult physicians and paediatricians practicing in allergy. The recommendations are evidence graded. During the development of these guidelines, all BSACI members were included in the consultation process using a web‐based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are clinical classification of rhinitis, aetiology, diagnosis, investigations and management including subcutaneous and sublingual immunotherapy. There are also special sections for children, co‐morbid associations and pregnancy. Finally, we have made recommendations for potential areas of future research.

1 January 2001 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
SWSamantha M. Walker
Samantha M. Walker
GPGiovanni B. Pajno
Giovanni B. Pajno
MLMarcia Torres Lima
Marcia Torres Lima
DWDuncan R. Wilson
Duncan R. Wilson
SDStephen R. Durham
Stephen R. Durham

22 March 2007 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
RPR. J. Powell
R. J. Powell
GTG. L. Du Toit
G. L. Du Toit
NSN. Siddique
N. Siddique
SLS. C. Leech
S. C. Leech
TDT. A. Dixon
T. A. Dixon
SNS. M. Nasser
S. M. Nasser
Summary: This guidance for the management of patients with chronic urticaria and angio‐oedema has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is aimed at both adult physicians and paediatricians practising in allergy. The recommendations are evidence graded. During the development of these guidelines, all BSACI members were included in the consultation process using a web‐based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking a consensus was reached by the experts on the committee. Included in this guideline are clinical classification, aetiology, diagnosis, investigations, treatment guidance with special sections on children with urticaria, and the use of antihistamines in women who are pregnant or breastfeeding. Finally, we have made recommendations for potential areas of future research.